Attorney Advertising. Keller Rohrback L.L.P. (www.krcomplexlit.com)
is investigating possible consumer claims against Pfizer, Inc. (NYSE:
PFE) relating to its recent recall of certain
lots of Lo/Ovral®-28 and Norgestrel birth control pills that were
sold in the U.S. This investigation focuses on the expenses incurred by
consumers as a result of the recalled birth control pills, such as the
cost of the pills, back-up methods of birth control, pregnancy tests,
and/or consultations with a physician, as recommended by Pfizer, due to
this recall.
On January 31, 2012, Pfizer voluntarily recalled approximately 1 million
packets of the Lo/Ovral®-28 Tablets (norgestrel and ethinyl estradiol)
and the Norgestrel and Ethinyl Estradiol Tablets (generic). The packets
of birth control pills typically have 21 tablets that contain active
ingredients and seven tablets of inert ingredients or “placebo” pills.
However, the recalled birth control packs may contain the wrong number
of each type of tablet and the tablets may be out of sequence. According
to a Pfizer news release, “As a result of this packaging error, the
daily regimen for these oral contraceptives may be incorrect and could
leave women without adequate contraception, and at risk for unintended
pregnancy.” Pfizer recommends that women who have used Lo/Ovral®-28 or
Norgestrel pills over the last several months should consult with their
doctor and begin using a non-hormonal birth control method immediately.
If you were prescribed Lo/Ovral®-28 or Norgestrel birth control pills
that are the subject of the recall and paid money as a result, or if you
would like more information regarding our investigation, please contact
paralegal Maggie Norton or attorneys Havila Unrein, Sharon Hritz or
Gretchen Freeman Cappio at (800) 776-6044 or via email at consumer@kellerrohrback.com.
Keller Rohrback, with offices in Seattle, Phoenix, New York and Santa
Barbara, is proud to offer its expertise in consumer cases to clients
nationwide.
Attorney Advertising. Prior Results Do Not Guarantee A Similar Outcome.

Add GEN to your Inbox FREE!
Subscribe today to our complimentary e-Newsletters and stay abreast of the latest biotech news and trends.